Proxy Materials for RegeneRx Annual Meeting - September 10, 2014

Link to document.

Shareholder letter - Thursday May 22, 2014

Link to document.

RegeneRx Pipeline

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.

Latest News:

January 28, 2015
RegeneRx and G-treeBNT Create Joint Venture to Develop RGN-259 in the U.S.

December 29, 2014
RegeneRx Partner Submits Phase IIB/III IND to Korean Health Authority for RGN-259 for the Treatment of Dry Eye Syndrome

November 25, 2014
Researchers Report Thymosin Beta 4 is Cardioprotective in Pulmonary Hypertension/Heart Failure Model

November 6, 2014
RegeneRx Announces Management Changes

November 3, 2014
U.S. Patent Office Significantly Extends the Term of Three RegeneRx Patents

October 24, 2014
Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model